Novartis stock holds firm on recent earnings momentum
Published on 07/19/2026 at 20:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis (CH0012005267) is supported by a 2025 base that included USD 50.3 billion in net sales, USD 18.1 billion in core operating income, and core earnings per share of USD 7.78. Those figures frame the stock as investors weigh scale, profitability, and cash generation against a large-cap pharma peer group.
USD 50.3 billion in sales
For fiscal 2025, Novartis reported net sales of USD 50.3 billion, up 12% at constant currencies from the prior year. Core operating income reached USD 18.1 billion in 2025, which the company said translated into a core operating margin of 36.0%.
That margin matters because it shows how much of the revenue base is converted into operating profit. In a sector where patent cycles can compress earnings quickly, a 36.0% core margin gives the company a comparatively resilient earnings structure.
EPS rose to USD 7.78
Core diluted EPS was USD 7.78 in fiscal 2025, compared with USD 6.34 in 2024. The change marks a year-on-year increase of about 22.7%, a useful comparison for investors tracking whether sales growth is translating into per-share earnings.
Novartis also reported free cash flow of USD 14.7 billion in 2025, which supports capital returns and pipeline investment. Net debt stood at USD 11.0 billion at year-end 2025, a level that remains manageable for a company of this size and cash profile.
Cash and leverage
The balance-sheet picture is part of the stock story because free cash flow and net debt often shape pharma valuation more than short-term trading noise. With USD 14.7 billion in free cash flow and USD 11.0 billion in net debt, the company entered 2026 with room to fund launches, dividends, and research spending.
For investors, the relevant question is whether 2025 becomes a repeatable earnings run-rate or a peak year. The answer now depends on prescription trends, pipeline execution, and how much of the USD 50.3 billion sales base stays protected.
Cosentyx still matters
One of the most visible product lines is Cosentyx, which remains a major revenue contributor in Novartis's immunology portfolio. The product matters because large branded medicines can anchor sales even when newer launches are still scaling.
Product concentration is part of the valuation debate, but the 2025 numbers show that the group is not dependent on a single quarterly spike. Net sales of USD 50.3 billion, core operating income of USD 18.1 billion, and core EPS of USD 7.78 give the stock a measurable earnings base.
Trading near scale
As of 19 July 2026, the share price line is not included here, so the more relevant market anchor is the 2025 earnings profile and the company size behind it. Novartis remains one of Europe's largest drugmakers, and that scale is part of why the stock often trades on earnings quality rather than revenue alone.
The 2025 comparison is still the cleanest read-through: sales up 12% at constant currencies, core EPS up about 22.7%, and free cash flow at USD 14.7 billion. Those are the numbers that will matter most until the next report resets the market focus.
Novartis 2025 earnings and strategy
The investor page contains the annual report and latest presentations behind the 2025 revenue, margin, EPS, cash flow, and debt figures.
Cosentyx revenue
Cosentyx is a key product because it helps Novartis spread revenue across immunology, oncology, and cardiovascular treatment areas. In a year when the company reported USD 50.3 billion in sales, that kind of portfolio breadth reduces the risk that one product line dominates the entire stock thesis.
2025 earnings base
The stock is best read through the 2025 earnings base: USD 18.1 billion in core operating income, a 36.0% margin, USD 7.78 in core EPS, USD 14.7 billion in free cash flow, and USD 11.0 billion in net debt. Together, those figures describe a profitable global pharma platform rather than a one-quarter trading story.
Novartis at a glance
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: SIX: NOVN
- Trading venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
